> Skip repeated content

Revision Anterior Cruciate Ligament Reconstruction in Adolescents

IRB Number: 10122

August 16, 2010

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Frank A. Cordasco, MD, MS


Keith R. Reinhardt, MD
Sommer Hammoud, MD
Andrea Bowers, MD
David W. Altchek, MD
Answorth A. Allen, MD
Robert G. Marx, MD
Andrew D. Pearle, MD
Anil S. Ranawat, MD
Anne M. Kelly, MD
Beth E. Shubin Stein, MD
Bryan T. Kelly, MD

David M. Dines, MD
Joshua S. Dines, MD
Edward V. Craig, MD. MPH
Howard Anthony Rose, MD
Jo A. Hannafin, MD, PhD
John D. MacGillivray, MD
Michael J. Maynard, MD
Riley J. Williams III, MD
Russell F. Warren, MD
Sabrina M. Strickland, MD
Scott A. Rodeo, MD
Stephen Fealy, MD
Steve J. O’Brien, MD, MBA
Struan H. Coleman, MD, MPH
Thomas L. Wickiewicz, MD


Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.

Inclusion/Exclusion Criteria

Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.

Contact Information

Keith Reinhardt, MD